5,5-diphenyl-2-(2-piperidin-1-ylethyl)-1,3-dioxolan-4-one;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5,5-diphenyl-2-(2-piperidin-1-ylethyl)-1,3-dioxolan-4-one;hydron;chloride
• 化学式: C22H26ClNO3
• 分子量: 387.9
• InChiKey: JXNQXJVDHXGEPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  38.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
  申请人：Johnson Bankole A.

  公开号：US20100076006A1

  公开（公告）日：2010-03-25

  The present invention provides for the use of combinations of drugs to treat addictive disorders.

  本发明提供了利用药物组合治疗成瘾性障碍的方法。
• USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS
  申请人：Kovacs Bruce

  公开号：US20090318520A1

  公开（公告）日：2009-12-24

  The present invention generally relates to the use of drugs for the treatment of neurobehavioral disorders or symptoms of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters.

  本发明一般涉及使用药物治疗与三单胺调节系统（TMMS）功能障碍相关的神经行为障碍或症状。更具体地，该发明描述了通过单独或与其他药物联合给予适当的异吲哚衍生物以在血清素、多巴胺和去甲肾上腺素转运体上提供相对平等的抑制作用，用于治疗神经行为障碍和/或治疗或预防神经行为障碍症状的方法。
• Use of sulfamate derivatives for treating impulse control disorders
  申请人：——

  公开号：US20010023254A1

  公开（公告）日：2001-09-20

  Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: 1 wherein X is CH 2 or oxygen, and R 1 , R 2 , R 3 , R4 and R 5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.

  冲动控制障碍(ICD)的特征为在无法抵制的冲动下进行有害行为。ICD的本质特征是无法抵制冲动、驱动力或诱惑，并执行对个人或他人有害的行为。本发明涉及使用以下公式的磺酰胺类治疗或预防ICD的方法：1其中X为CH2或氧，R1、R2、R3、R4和R5如本文所定义。此外，本发明还揭示了含有公式(I)化合物的制药组合物以及其使用方法和中间体。